Diabetes & Metabolic Syndrome-Clinical Research & Reviews最新文献

{"title":"Prevalence of latent and overt polyautoimmunity in type 1 diabetes: A systematic review and meta-analysis","authors":"Mariana Celis-Andrade ,&nbsp;Victoria Morales-González ,&nbsp;Manuel Rojas ,&nbsp;Diana M. Monsalve ,&nbsp;Yeny Acosta-Ampudia ,&nbsp;Mónica Rodríguez-Jiménez ,&nbsp;Yhojan Rodríguez ,&nbsp;Carolina Ramírez-Santana","doi":"10.1016/j.dsx.2024.103087","DOIUrl":"10.1016/j.dsx.2024.103087","url":null,"abstract":"<div><h3>Background</h3><p>Patients afflicted by type 1 diabetes (T1D) exhibit polyautoimmunity (PolyA). However, the frequency and distribution of PolyA in T1D is still unknown.</p></div><div><h3>Objective</h3><p>We conducted a systematic review and meta-analysis to define the prevalence of latent and overt PolyA in individuals with T1D.</p></div><div><h3>Methods</h3><p>Following PRISMA guidelines, a comprehensive search across medical databases identified studies on latent and overt PolyA in T1D. Two researchers independently screened, extracted data, and assessed study quality. A random effects model was utilized to calculate the pooled prevalence, along with its corresponding 95 % confidence interval (CI), for latent PolyA and overt PolyA. Meta-regression analysis was conducted to study the effect of study designs, age, sex, and duration of disease on pooled prevalence.</p></div><div><h3>Results</h3><p>A total of 158 articles, encompassing a diverse composition of study designs were scrutinized. The analysis included 270,890 individuals with a confirmed diagnosis of T1D. The gender was evenly distributed (50.30 % male). Notably, our analysis unveiled an overt PolyA prevalence rate of 8.50 % (95 % CI, 6.77 to 10.62), with North America having the highest rates (14.50 %, 95 % CI, 7.58 to 24.89). This PolyA profile was further characterized by a substantial incidence of concurrent autoimmune thyroid disease (7.44 %, 95 % CI, 5.65 to 9.74). Moreover, we identified a notable prevalence of latent PolyA in the T1D population, quantified at 14.45 % (95 % CI, 11.17 to 18.49) being most frequent in Asia (23.29 %, 95 % CI, 16.29 to 32.15) and Oceania (21.53 %, 95 % CI, 16.48 to 27.62). Remarkably, this latent PolyA phenomenon primarily featured an array of autoantibodies, including rheumatoid factor, followed by Ro52, thyroid peroxidase antibodies, and thyroglobulin antibodies. Duration of the disease was associated with a highest frequency of latent (β: 0.0456, P-value: 0.0140) and overt PolyA (β: 0.0373, P-value: 0.0152). No difference in the pooled prevalence by study design was observed.</p></div><div><h3>Conclusion</h3><p>This meta-analysis constitutes a substantial advancement in the realm of early detection of PolyA in the context of T1D. Individuals with T1D should regularly undergo assessments to identify potential concurrent autoimmune diseases, especially as they age.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103087"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141793806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights of the current issue","authors":"Ningjian Wang (Associate Editor) ,&nbsp;Anoop Misra (Editor-in-Chief)","doi":"10.1016/j.dsx.2024.103117","DOIUrl":"10.1016/j.dsx.2024.103117","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103117"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142326670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Computational approaches for clinical, genomic and proteomic markers of response to glucagon-like peptide-1 therapy in type-2 diabetes mellitus: An exploratory analysis with machine learning algorithms","authors":"Angelina Thomas Villikudathil ,&nbsp;Declan H. Mc Guigan ,&nbsp;Andrew English","doi":"10.1016/j.dsx.2024.103086","DOIUrl":"10.1016/j.dsx.2024.103086","url":null,"abstract":"<div><h3>Introduction</h3><p>In 2021, the International Diabetes Federation reported that 537 million people worldwide are living with diabetes. While glucagon-like peptide-1 agonists provide significant benefits in diabetes management, approximately 40 % of patients do not respond well to this therapy. This study aims to enhance treatment outcomes by using machine learning to predict individual response status to glucagon-like peptide-1 therapy.</p></div><div><h3>Methods</h3><p>We analysed a type-2 diabetes mellitus dataset from the Diastrat cohort, recruited at the Northern Ireland Centre for Stratified Medicine. The dataset included individuals prescribed glucagon-like peptide-1 therapy, with response status determined by glycated haemoglobin levels of ≤53 mmol/mol. We identified genomic and proteomic markers and developed machine learning models to predict therapy response.</p></div><div><h3>Results</h3><p>The study found 5 genomic variants and 45 proteomic markers that help differentiate glucagon-like peptide-1 therapy responders from non-responders, achieving 95 % prediction accuracy with a machine learning model.</p></div><div><h3>Conclusion</h3><p>This study demonstrates the potential of machine learning in predicting the response to glucagon-like peptide-1 therapy in individuals with type-2 diabetes mellitus. These findings suggest that integrating genomic and proteomic data can significantly enhance personalized treatment approaches, potentially improving outcomes for patients who might otherwise not respond well to glucagon-like peptide-1 therapy. Further research and validation in larger cohorts are necessary to confirm these results and translate them into clinical practice.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103086"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141789467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Out-of-pocket direct cost of ambulatory care of type 2 diabetes in Delhi: Estimates from the Delhi diabetes community-II (DEDICOM-II) survey","authors":"Swapnil Rawat,&nbsp;Neetu Bansal,&nbsp;Ramasheesh Yadav,&nbsp;Siddhi Goyal,&nbsp;Jitender Nagpal","doi":"10.1016/j.dsx.2024.103089","DOIUrl":"10.1016/j.dsx.2024.103089","url":null,"abstract":"<div><h3>Background &amp; aim</h3><p>Much of the cost data from India is restricted to patients recruited purely from healthcare institutions and do not explore determinants. Therefore, the out of pocket expenditure for ambulatory diabetes care was evaluated in Delhi.</p></div><div><h3>Methods</h3><p>The DEDICOM-II survey used a two-stage probability-proportionate-to-size(systematic) cluster design. Thirty clusters were chosen to recruit 25 to 30 subjects per area. We used questionnaires to estimate the direct out-of-pocket expenditure (OOPE) on drugs, investigations, consultation and travel, excluding hospitalization, and then analysed its determinants and impact on quality of care.</p></div><div><h3>Results</h3><p>We enrolled 843 subjects with a mean age of 53.1 years. The annual direct OOPE on ambulatory care of diabetes was US$ 116.3 (95 % CI 93.8–138.9) or INR 8074.8 (95 % CI 6512.9–9636.7), corresponding to 3.6 %(95 % CI 2.9–4.3) of the yearly family income. The burden of expenses was disproportionately higher for those visiting private providers from lower-income groups(19.1 %). Duration of disease and treatment with insulin predicted higher annual OOPE while care at public facilities was less expensive. Cost was higher for those adhering to the recommended processes of care. Quality of care was better for institutional care and worse for alternative medicine or self-care.</p></div><div><h3>Conclusions</h3><p>The study provides representative estimates of the high cost of diabetes management in Delhi across the socio-economic and care provider spectra. Poorer patients suffer a high financial burden from diabetes, highlighting the need for enhancing equity in diabetes care.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103089"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141849583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lifestyle modifies the associations of early-life smoking behaviors and genetic susceptibility with type 2 diabetes: A prospective cohort study involving 433,872 individuals from UK Biobank","authors":"Xuanwei Jiang,&nbsp;Guangrui Yang,&nbsp;Nannan Feng,&nbsp;Xihao Du,&nbsp;Lan Xu,&nbsp;Victor W. Zhong","doi":"10.1016/j.dsx.2024.103090","DOIUrl":"10.1016/j.dsx.2024.103090","url":null,"abstract":"<div><h3>Background</h3><p>To investigate whether and what lifestyle factors in later life modify the associations of early-life smoking behaviors and genetic susceptibility with type 2 diabetes (T2D).</p></div><div><h3>Methods</h3><p>In the UK Biobank, in utero tobacco exposure (n = 354,493) and age of smoking initiation (n = 353,557) were self-reported. A composite lifestyle score was calculated based on diet, physical activity, nicotine exposure, sleep duration, and BMI. Hazard ratio (HR) and absolute risk difference (ARD) were used to estimate the associations of early-life smoking behaviors and genetic risk with incident T2D, as well as the effect modification of the lifestyle score.</p></div><div><h3>Results</h3><p>During a median follow-up of 14.6 years, the HRs (95 % CIs) of T2D for in utero tobacco exposure, and smoking initiation in adulthood, adolescence, and childhood, compared with no smoking behavior, were 1.19 (1.16–1.23), 1.34 (1.29–1.39), 1.58 (1.53–1.64), 2.22 (2.11–2.32), respectively (<em>P</em> for trend&lt;0.001). Early-life smoking behaviors and high genetic risk (vs no smoking behavior and low genetic risk) were associated with a 302%–593 % higher T2D risk (<em>P</em> for additive interaction&lt;0.05). Compared to participants with early-life smoking behaviors, high genetic risk, and an unfavorable lifestyle, those who adhered to a favorable lifestyle had a lower T2D risk in all subgroups (HRs from 0.05 to 0.36 and ARD from −14.97 % to −9.51 %), with the highest ARD attributable to lifestyle in participants with early-life smoking behaviors and high genetic risk.</p></div><div><h3>Conclusions</h3><p>The T2D risk associated with early-life smoking behaviors and genetic risk was modified by a favorable lifestyle.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103090"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141842421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"District-level epidemiology and sociodemographic determinants of noncommunicable diseases - results the National Family Health Survey −5 (2019–21)","authors":"Vaitheeswaran Kulothungan,&nbsp;Leena Mascarenhas,&nbsp;Priyanka Das,&nbsp;Prashant Mathur","doi":"10.1016/j.dsx.2024.103085","DOIUrl":"10.1016/j.dsx.2024.103085","url":null,"abstract":"<div><h3>Background</h3><p>Noncommunicable diseases (NCDs) are the leading cause of adult mortality in India. However, the data regarding the prevalence of NCD risk factors at district level is scarce. This study aims to analyse and map NCD risk factors at the state and district levels, exploring sociodemographic influences on these risks in Indian males and females.</p></div><div><h3>Methods</h3><p>We analyzed National Family Health Survey-5 database and used the prevalence estimates to create choropleth maps, enabling us to examine the geographical variations in NCD risk factors at the district level in India.</p></div><div><h3>Results</h3><p>Districts in the Satluj-Yamuna plains, western Rajasthan, and the northeastern regions exhibited clusters with a prevalence of high blood pressure exceeding 30.1 %. Northeastern districts showed over 40 % prevalence of current tobacco use, while high alcohol consumption clusters were observed in the northeastern and Telangana districts. Southern districts showed clusters of both obesity (as measured by BMI) and highest rates of oral, breast, and cervical cancer screening, moreover districts in Tamil Nadu exhibited notable clusters of raised blood glucose prevalence.</p></div><div><h3>Conclusion</h3><p>Our analysis revealed variations in the prevalence of NCD risk factors at both the state and district levels. Accordingly, this study ranks districts based on the NCD burden, offering valuable insights to state and district teams to devise targeted measures for the prevention and control of NCDs, particularly in the most heavily affected districts.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103085"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141849474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chorionicity and gestational diabetes mellitus in twin pregnancies in relation to placental weight","authors":"Mohammed Rohi Khalil ,&nbsp;Fatma Demircioglu ,&nbsp;Catherine Vinge François ,&nbsp;Sören Möller ,&nbsp;Erling Andreasen","doi":"10.1016/j.dsx.2024.103093","DOIUrl":"10.1016/j.dsx.2024.103093","url":null,"abstract":"<div><h3>Background</h3><p>Gestational diabetes mellitus (GDM) is glucose intolerance first detected during pregnancy. Twin pregnancies have a higher risk of GDM, likely due to increased placental mass and elevated placental lactogen levels.</p></div><div><h3>Objective</h3><p>The aims of this study were 1) to assess the impact of chorionicity on the development of GDM in twin pregnancies and 2) to assess a possible association between placenta weight and the development of GDM.</p></div><div><h3>Methods</h3><p>We conducted a prospective cohort study of all women with twin pregnancies (N = 819) at the department of Obstetrics and Gynecology, Lillebaelt University Hospital, Kolding, Denmark, between January 1, 2007 and April 30, 2019. Information on chronicity was determined at the first visit with ultrasonic imaging, during weeks’ gestation 11–13. Oral glucose-tolerance test was performed to diagnose gestational diabetes mellitus.</p></div><div><h3>Results</h3><p>Among 819 twins, 17.8 % were monochorionic twins and 82.2 % were dichorionic twins. There were no statistically significant difference of GDM prevalence between monochorionic twins group 7.4 % and dichorionic twins group 9.8 % (P = 0.42). Placenta's weight in dichorionic twins was larger compared with monochorionic twins. No association was found between the weight of placenta and the prevalence of GDM (P = 0.21), even after adjustment for body mass index, gestational age, and fertility treatment (P = 0.87).</p></div><div><h3>Conclusions</h3><p>Our study could not find an association between chorionicity, placental weight, and GDM. It is, therefore, possible that twin pregnancies, regardless of chorionicity and placental weight, have the same risk for GDM.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103093"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of stevia on blood glucose and HbA1C: A meta-analysis","authors":"Marzieh Zare ,&nbsp;Mobina Zeinalabedini ,&nbsp;Soraiya Ebrahimpour-Koujan ,&nbsp;Nick Bellissimo ,&nbsp;Leila Azadbakht","doi":"10.1016/j.dsx.2024.103092","DOIUrl":"10.1016/j.dsx.2024.103092","url":null,"abstract":"<div><h3>Background</h3><p>The study investigates substituting non-nutritive sweeteners (NNS) for sugar to address health concerns related to excess sugar intake. It specifically examines how stevia affects insulin and blood glucose levels. The systematic review and meta-analysis aim to evaluate stevia's impact on glycemic indices.</p></div><div><h3>Methods</h3><p>We conducted a systematic review and meta-analysis following PRISMA guidelines, including 26 studies with 1439 participants. The PROSPERO registration number for this research is CRD42023414411. We systematically searched PubMed (MEDLINE), Scopus, Web of Science, and Google Scholar. Additionally, we thoroughly reviewed the reference lists of the articles we extracted and relevant reviews. Two evaluators independently carried out screening, quality assessment, and data extraction. The GRADE (grading of recommendations, assessment, development, and evaluation) approach was utilized to evaluate the certainty of the evidence.</p></div><div><h3>Results</h3><p>Stevia consumption was associated with significantly reducing blood glucose levels (WMD: −3.84; 95 % CI: −7.15, −0.53; P = 0.02, low certainty), especially in individuals with higher BMI, diabetes, and hypertension. Dose-response analysis revealed a decrease in blood glucose for ≥3342 mg/day of stevia consumption. Stevia consumption has been shown to reduce blood glucose levels within 1–4 months, as evidenced by dose-response analysis (less than 120 days) and subgroup analysis (more than four weeks). However, stevia did not significantly affect insulin concentration or HbA1C levels (very low and low certainty, respectively).</p></div><div><h3>Conclusions</h3><p>Low certainty evidence showed that stevia improved blood glucose control, especially when consumed for less than 120 days. However, more randomized trials with higher stevia dosages are required.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103092"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enrollment of Black, Indigenous and People of Color (BIPOC) and female participants in the US diabetes trials spanning 2000 to 2020: A chronological survey","authors":"Jingyi Zhang ,&nbsp;Miaoguan Peng ,&nbsp;Jianfeng Li ,&nbsp;Likang Li ,&nbsp;Xuerui Bai ,&nbsp;Lehana Thabane ,&nbsp;Gregory Yh Lip ,&nbsp;Harriette GC. Van Spall ,&nbsp;Guowei Li","doi":"10.1016/j.dsx.2024.103074","DOIUrl":"10.1016/j.dsx.2024.103074","url":null,"abstract":"<div><h3>Aims</h3><p>Little is known about the enrollment practice of both Black, Indigenous and People of Color (BIPOC) and females in the US diabetes trials. We aimed to perform a chronological survey to evaluate the enrollment of BIPOC and female participants in the US diabetes randomized controlled trials (RCTs) over the past two decades.</p></div><div><h3>Methods</h3><p>We searched databases to systematically include the US diabetes RCTs from 2000 January 1st to 2020 December 31st. Primary outcome was the adequate enrollment of both BIPOC and females, defined by the participation to prevalence ratio (PPR) &gt; 0.8. We tested the temporal trend in adequate enrollment over time and used logistic regression analysis to explore the relationship between adequate enrollment and trial characteristics.</p></div><div><h3>Results</h3><p>A total of 69 US diabetes trials were included for analyses, with a median BIPOC and female enrollment percentage of 29.0 % and 45.4 % respectively. There were 22 (31.9 %) trials with adequate enrollment of both BIPOC and females. No significant trend of adequate enrollment percentage of BIPOC and females over time was observed (<em>P</em> = 0.16). Of trial types, those with medication interventions were significantly related to decreased odds of adequate enrollment, when compared to trials with non-drug interventions (odds ratio = 0.29, 95 % confidence interval: 0.11–0.84).</p></div><div><h3>Conclusions</h3><p>Less than one third of the US diabetes trials adequately enrolled both BIPOC and females over the past two decades, and no temporal improvement in BIPOC and female participant enrollment was observed. These results highlight the need for more endeavors to mitigate inadequate representation regarding BIPOC and female enrollment in diabetes trials.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103074"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141691856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of coffee and its bioactive compounds on the risks of type 2 diabetes and its complications: A comprehensive review","authors":"Almahi I. Mohamed ,&nbsp;Ochuko L. Erukainure ,&nbsp;Veronica F. Salau ,&nbsp;Md Shahidul Islam","doi":"10.1016/j.dsx.2024.103075","DOIUrl":"10.1016/j.dsx.2024.103075","url":null,"abstract":"<div><h3>Background</h3><p>Coffee beans have a long history of use as traditional medicine by various indigenous people. Recent focus has been given to the health benefits of coffee beans and its bioactive compounds. Research on the bioactivities, applications, and effects of processing methods on coffee beans' phytochemical composition and activities has been conducted extensively. The current review attempts to provide an update on the biological effects of coffee on type 2 diabetes (T2D) and its comorbidities.</p></div><div><h3>Methods</h3><p>Comprehensive literature search was carried out on peer-reviewed published data on biological activities of coffee on <em>in vitro</em>, <em>in vivo</em> and epidemiological research results published from January 2015 to December 2022, using online databases such as PubMed, Google Scholar and ScienceDirect for our searches.</p></div><div><h3>Results</h3><p>The main findings were: firstly, coffee may contribute to the prevention of oxidative stress and T2D-related illnesses such as cardiovascular disease, retinopathy, obesity, and metabolic syndrome; secondly, consuming up to 400 mg/day (1–4 cups per day) of coffee is associated with lower risks of T2D; thirdly, caffeine consumed between 0.5 and 4 h before a meal may inhibit acute metabolic rate; and finally, both caffeinated and decaffeinated coffee are associated with reducing the risks of T2D.</p></div><div><h3>Conclusion</h3><p>Available evidence indicates that long-term consumption of coffee is associated with decreased risk of T2D and its complications as well as decreased body weight. This has been attributed to the consumption of coffee with the abundance of bioactive chemicals.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103075"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S187140212400136X/pdfft?md5=eb0e2a8cd5e009c11ab31f87f64a5067&pid=1-s2.0-S187140212400136X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141694595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}